search
Back to results

Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study (TIPPS)

Primary Purpose

Scleroderma, Systemic

Status
Unknown status
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
Cutaneous iontophoresis of treprostinil
Sponsored by
University Hospital, Grenoble
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Scleroderma, Systemic focused on measuring Treprostinil, Scleroderma, Iontophoresis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Cutaneous systemic scleroderma with sclerosed fingers

Exclusion Criteria:

  • pregnant or breast-feeding women
  • any chronic disease (in the control group)
  • smoking

Sites / Locations

  • CIC pharmacology - University Hopsital of Grenoble

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Cutaneous iontophoresis of Treprostenil

Cutaneous iontophoresis of placebo

Arm Description

Outcomes

Primary Outcome Measures

Area under the curve (AUC) of cutaneous blood flow
Cutaneous blood flow assessed with Laser Speckle Contrast Imaging (LSCI)

Secondary Outcome Measures

Treprostinil blood concentration
AUC of treprostinil concentration from the end of iontophoresis until 10 hours after iontophoresis
Treprostinil dermal concentration
AUC of treprostinil concentration in the dermis (collected with microdialysis) from the end of iontophoresis until 10 hours after iontophoresis

Full Information

First Posted
February 7, 2012
Last Updated
July 17, 2013
Sponsor
University Hospital, Grenoble
search

1. Study Identification

Unique Protocol Identification Number
NCT01554540
Brief Title
Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study
Acronym
TIPPS
Official Title
Pharmacodynamic and Pharmacokinetic Assessment of Treprostinil Iontophoresis on the Forearm and the Fingers
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Unknown status
Study Start Date
February 2012 (undefined)
Primary Completion Date
October 2013 (Anticipated)
Study Completion Date
February 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to assess skin blood flow after non-invasive local administration of treprostinil by using a low-intensity current (i.e. iontophoresis) on the forearm and the fingers of healthy volunteers and patients with systemic sclerosis. The investigators also aim at assessing the systemic bioavailability and dermal diffusion of treprostinil iontophoresis.
Detailed Description
Digital ulcerations are a complication of systemic sclerosis (SSc). Available treatments (i.e. IV iloprost) induce major adverse effects, limiting the use of such therapies. Iontophoresis is a non invasive route of administration of drugs. In experimental and clinical preliminary studies, the investigators have shown that iontophoresis of treprostinil on the forearm of healthy subjects induces a sustained increase in skin blood flux and that it is well tolerated (clinicaltrials.gov NCT01082484, manuscript in press). The investigators therefore aim at validating this proof of concept on the digits of SSc patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scleroderma, Systemic
Keywords
Treprostinil, Scleroderma, Iontophoresis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cutaneous iontophoresis of Treprostenil
Arm Type
Experimental
Arm Title
Cutaneous iontophoresis of placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Cutaneous iontophoresis of treprostinil
Intervention Description
Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
Primary Outcome Measure Information:
Title
Area under the curve (AUC) of cutaneous blood flow
Description
Cutaneous blood flow assessed with Laser Speckle Contrast Imaging (LSCI)
Time Frame
0, 15min, 30 min, 1h, 2h, 4h, 6h, 8h, 10h
Secondary Outcome Measure Information:
Title
Treprostinil blood concentration
Description
AUC of treprostinil concentration from the end of iontophoresis until 10 hours after iontophoresis
Time Frame
0, 15min, 30 min, 1h, 2h, 4h, 6h, 8h, 10h
Title
Treprostinil dermal concentration
Description
AUC of treprostinil concentration in the dermis (collected with microdialysis) from the end of iontophoresis until 10 hours after iontophoresis
Time Frame
1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Cutaneous systemic scleroderma with sclerosed fingers Exclusion Criteria: pregnant or breast-feeding women any chronic disease (in the control group) smoking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Luc Cracowski, MD
Organizational Affiliation
INSERM 003
Official's Role
Principal Investigator
Facility Information:
Facility Name
CIC pharmacology - University Hopsital of Grenoble
City
Grenoble
ZIP/Postal Code
38043
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
20860718
Citation
Blaise S, Roustit M, Millet C, Ribuot C, Boutonnat J, Cracowski JL. Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats. Br J Pharmacol. 2011 Feb;162(3):557-65. doi: 10.1111/j.1476-5381.2010.01045.x.
Results Reference
background
PubMed Identifier
16876881
Citation
Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci. 2006 Sep;27(9):503-8. doi: 10.1016/j.tips.2006.07.008. Epub 2006 Jul 31.
Results Reference
background
PubMed Identifier
11092203
Citation
Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol. 2000 Nov;12(6):527-33. doi: 10.1097/00002281-200011000-00009.
Results Reference
background
PubMed Identifier
15019750
Citation
Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004 Mar 27;56(5):619-58. doi: 10.1016/j.addr.2003.10.026.
Results Reference
background
PubMed Identifier
18077494
Citation
Murray AK, Moore TL, King TA, Herrick AL. Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis? Rheumatology (Oxford). 2008 Jan;47(1):76-9. doi: 10.1093/rheumatology/kem314.
Results Reference
background
PubMed Identifier
28387950
Citation
Gaillard-Bigot F, Roustit M, Jourdil JF, Stanke-Labesque F, Cracowski JL. Vascular Effects of Treprostinil Cutaneous Iontophoresis on the Leg, Finger, and Foot. J Clin Pharmacol. 2017 Sep;57(9):1215-1220. doi: 10.1002/jcph.898. Epub 2017 Apr 7. No abstract available.
Results Reference
derived

Learn more about this trial

Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study

We'll reach out to this number within 24 hrs